ReviewInternational journal of molecular medicine2020
Gut microbiota metabolites as integral mediators in cardiovascular diseases (Review).
Review in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 52 citations in OpenAlex.
- Gut microbiota-bile acid axis in cardiovascular disease: a spatiotemporal framework for predictive, preventive and personalised medicine.The EPMA journal · 2026Review
- Precision Lipid Management in the Era of Biotechnology and Artificial Intelligence: From Gene Editing to Smart Drug Delivery.Therapeutic innovation & regulatory science · 2026Review
- Mass spectrometry-based metabolomics for studying gut microbiota-derived metabolites in biological samples.Journal of food and drug analysis · 2026Review
- Sulfated Alfalfa Polysaccharides Enhance Post-Obesity Recovery Through Modulation of Gut Microbiota and Antioxidant Activity.Chemistry & biodiversity · 2026Article
- New Advances in the Mechanisms and Therapeutic Strategies of Gut Microbiota in Regulating Glycolipid Metabolism to Combat Atherosclerosis.Journal of cardiovascular translational research · 2026Review
- Gut microbial metabolites targeting JUN in renal cell carcinoma via IL-17 signaling pathway: network pharmacology approach.Molecular diversity · 2026Article
- Gut microbiota-cholesterol crosstalk in cardiovascular diseases: mechanisms, metabolites, and therapeutic modulation.Nutrition & metabolism · 2025Review
- High Salt Intake and Atherosclerosis Progression-Not Only via Blood Pressure: A Narrative Review.Nutrients · 2025Review
- Impact of gut microbiome on atrial fibrillation: Mechanistic insights and future directions in individualized medicine.World journal of cardiology · 2025Review
- Microbiota in Gut-Heart Axis: Metabolites and Mechanisms in Cardiovascular Disease.Comprehensive physiology · 2025Review
- Uncovering the molecular mechanisms of tonifying kidney and activating blood Decoction against myocardial fibrosis using network Pharmacology and experimental validation.Scientific reports · 2025Article
- Chemical interplay between gut microbiota and epigenetics: Implications in circadian biology.Cell chemical biology · 2025Review
- Identifying the Involvement of Gut Microbiota in Retinal Vein Occlusion by Mendelian Randomization and Genetic Correlation Analysis.Translational vision science & technology · 2025Article
- The oral-gut microbiota axis in cardiovascular diseases: mechanisms, therapeutic targets, and translational challenges.Frontiers in cellular and infection microbiology · 2025Review
- Article
- Association of dietary index for gut microbiota and cardiovascular diseases in American adults: evidence from National Health and Nutrition Examination Survey 1999-2018.Frontiers in nutrition · 2025Article
- Research Trends and Hotspots of Gut Microbiota and Its Metabolites in Cardiovascular Diseases: A Bibliometric Analysis.Journal of multidisciplinary healthcare · 2025Article
- Exploring synergistic effects ofHeliyon · 2024Article
- Aging-associated atrial fibrillation: A comprehensive review focusing on the potential mechanisms.Aging cell · 2024Review
- Role of Gut Microbial Metabolites in Cardiovascular Diseases-Current Insights and the Road Ahead.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs), such as atherosclerosis, hypertension, myocardial infarction and diabetic heart disease, are associated with high morbidity and mortality rates worldwide, and may also induce multiple organ failure in their later stages, greatly reducing the long‑term survival of the patients. There are several causes of CVDs, but after nearly a decade of investigation, researchers have found that CVDs are usually accompanied by an imbalance of gut microbiota and a decreased abundance of flora. More importantly, the metabolites produced by intestinal flora, such as trimethylamine and trimethylamine N‑oxide, bile acids, short‑chain fatty acids and aromatic amino acids, exert different effects on the occurrence and development of CVDs, as observed in the relevant pathways in the cells, which may either promote or protect against CVD occurrence. It is known that changes in the intestinal flora following antibiotic administration, diet supplementation with probiotics, or exercise, can interfere with the composition of the intestinal flora and may represent an effective approach to preventing or treating CVDs. The focus of this review was the analysis of gut microbiota metabolites to elucidate their effects on CVDs and to identify the most cost‑effective and beneficial methods for treating CVDs with minimal side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.